Work

A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.2556

Authors: Igor Puzanov, Patricia LoRusso, Kyriakos P. Papadopoulos, Christopher T. Chen, Yvan LeBruchec, Xiaomin He, Thierry Cousin, Karin Havenith, Joseph Boni, Johanna C. Bendell

Institutions: Roswell Park Comprehensive Cancer Center, Yale Cancer Center, South Texas Accelerated Research Therapeutics, Stanford Medicine, Adc Therapeutics (Switzerland), Sarah Cannon, Tennessee Oncology

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3169352193

Cites:

Cited by: 5

Related to: 10